Browse the evidence

Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.

Semaglutide is the most effective GLP-1 receptor agonist for improving glycemic control and promoting weight loss in T2DM patients.

Emerging oral therapies could complement or serve as alternatives to approved injectable treatments for long-term weight management.

Practitioners should consider these oral therapies as viable options alongside injectables.

Preconception weight optimization in women with obesity is important to reduce maternal and fetal risks.

Practitioners should prioritize weight management in women with obesity planning for pregnancy.

Average A1c decreased from 8.9% ± 1.3% to 7.6% ± 1.5% over 6 months (P < 0.001).

Clinicians may expect improvements in glycemic control with semaglutide in T2DM patients.

Body weight decreased from 123.9 ± 23.5 kg to 118.9 ± 22.9 kg over 6 months (P < 0.001).

Clinicians may observe weight loss in T2DM patients treated with semaglutide.

Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.

These agonists may offer new treatment options for diabetes and obesity.

Newer anti-obesity medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight.

Practitioners should consider these medications for patients seeking significant weight loss.

Weight loss of more than 10% may reduce obesity-associated cancer incidence.

Encouraging significant weight loss may be a viable strategy for reducing cancer risk in obese patients.

GLP-1 agonists are associated with favorable hemoglobin A1C levels and weight loss in type 1 diabetic patients.

GLP-1 agonists may be recommended for type 1 diabetes patients aiming for better glycemic control and weight management.

Tirzepatide treatment shows a potent glucose-lowering effect and promotes weight loss with minimal GI adverse effects.

Tirzepatide may be considered for patients needing effective glucose control and weight loss with fewer gastrointestinal side effects.

Semaglutide had substantial effects on multiple secondary alcohol-related and somatic outcomes.

Semaglutide may improve various aspects of health related to alcohol use disorder in addition to reducing drinking.

Semaglutide resulted in a similar reduction in body weight across frailty subgroups.

Semaglutide can be used effectively for weight management in patients with obesity-related HFpEF, regardless of frailty status.

Semaglutide 2.4 mg reduces body weight by an estimated mean change ranging from -9.40% to -16.42% in an East Asian population.

Practitioners can consider semaglutide 2.4 mg as an effective option for weight loss in East Asian adults with obesity.

A 12-week partial meal replacement (PMR) diet is effective for weight loss in overweight or obese patients after ischemic stroke, with 52.9% of participants achieving ≥5% weight loss compared to 11.9% in the standard care group.

Healthcare providers can consider PMR diets as a viable option for weight management in stroke patients.

GLP-1 receptor agonists or co-agonists have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.

Practitioners may consider GLP-1 receptor agonists as effective options for weight management and improving cardiometabolic health.

Endoscopic sleeve gastroplasty (ESG) has demonstrated durable weight loss, favorable safety, and superior cost-effectiveness compared to pharmacotherapy alone.

Practitioners may consider ESG as a viable option for patients seeking effective weight loss.

Combination strategies using endoscopic bariatric therapies (EBTs) and anti-obesity medications (AOMs) result in greater total-body weight loss than either modality alone.

Combining EBTs with AOMs may enhance weight loss outcomes for patients.

Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c.

Practitioners can consider semaglutide as an effective treatment for reducing BMI and improving glycemic control in obese T2DM patients.

Lifestyle modifications can mitigate cancer risk associated with obesity.

Encouraging lifestyle changes can be a key strategy in cancer prevention efforts.

Novel medications such as GLP-1 agonists have demonstrated sustained weight loss in patients with obesity.

Practitioners can consider GLP-1 agonists as a treatment option for obesity.

The FDA authorizes the use of injectable semaglutide for the treatment of obesity.

Practitioners can consider semaglutide as an approved treatment option for obesity in the U.S.

Bariatric surgery is the most effective treatment for patients with Type 2 diabetes mellitus (T2DM) and obesity.

Clinicians should consider bariatric surgery as a primary treatment option for patients with T2DM and obesity.

Metabolic surgery, intensive lifestyle modification, and pharmacologic approaches are viable options for achieving diabetes remission.

Practitioners should consider these options early in the disease course for better outcomes.

A comprehensive approach is the best way to manage weight.

Practitioners should consider a multifaceted approach to obesity treatment.